Cambrian Bio to Present Data on ATX-304 at American Diabetes Association Scientific Sessions
Cambrian Bio is set to present two posters on its lead therapeutic, ATX-304, at the American Diabetes Association's 86th Scientific Sessions in New Orleans. ATX-304 is a novel oral small molecule that activates AMPK and mitochondrial pathways, currently in clinical development for obesity and cardiometabolic diseases. The presentations will include data from a Phase 1b study in prediabetic obese participants and research on ATX-304's mechanism of action, highlighting its potential as a new treatment for metabolic decline. 
